Oculis Holding AG

OCS Healthcare Biotechnology

Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.

7.29 0.11 −1.49%
Market cap
$456.8M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
10.51
Beneish M
n/a
Dividend safety
n/a
Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 3 3 4
P/E ratio
107.67 0.00 0.00 0.00 0.00
P/S ratio
0.00 0.00 0.00 881.46 720.95
Altman Z-Score
(1.45) (6.55) 4.86 3.01 10.51
Altman Z″-Score (non-manufacturers)
(1.17) (14.33) (0.97) (6.88) 2.59
P/FCF ratio
0.00 0.00 0.00 0.00 0.00
P/Operating CF
(10.51) (1.59) (28.44) (62.23) (57.88)
P/B ratio
0.00 0.00 3.36 8.24 4.41
EV/Sales
0.00 0.00 0.00 739.37 545.04
EV/EBITDA
0.00 0.00 0.00 0.00 0.00
EV/FCF
(14.97) (2.80) (3.63) (10.62) (9.65)
Current Ratio
11.81 1.97 5.29 2.37 5.96
Net Debt/EBITDA
(5.16) (3.20) 1.13 1.34 2.60
Debt/Equity
(1.87) (1.25) 0.01 0.01 0.01
ROE
0.00% 47.88% (11,509.96%) (103.79%) (74.65%)
ROA
0.00% (79.25%) (119.02%) (73.79%) (56.67%)
ROIC
(120.78%) (391.93%) (1,747.97%) 0.00% 0.00%
Return on Tangible Assets
(41.83%) (322.43%) (108.01%) (140.51%) (54.17%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00
Earnings Yield
0.93% (103.29%) (103.46%) (13.59%) (11.37%)
Free Cash Flow Yield
(9.82%) (152.83%) (19.39%) (7.90%) (7.83%)
Free Cash Flow per Share
(5.46) (10.03) (2.01) (1.34) (1.56)
Book value per Share
(24.01) (34.35) 3.49 2.06 4.53
Free Cash Flow
(15.16) (29.99) (60.03) (54.22) (81.70)
EV/EBIT
0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates